Qiagen Receives FDA Clearance for New Bloodstream Infection Test Panel
Qiagen N.V. (NYSE:QGEN) received U.S. Food and Drug Administration clearance for its QIAstat-Dx BCID GPF Plus AMR panel, marking the company's entry into the bloodstream infection testing market in the United States. The automated test detects 20 gram-positive bacterial and fungal targets along with antimicrobial resistance markers within an hour using Qiagen’s widely deployed platform. The clearance follows strong Q2 financial results for Qiagen, including flat net sales of $535 million and a rise in adjusted diluted EPS to $0.62 year-over-year. The company reaffirmed its full-year 2026 guidance despite challenges such as declining respiratory testing sales and regional demand softness. Qiagen also announced the appointment of Jonathan Pratt as CEO, effective September 1, succeeding Thierry Bernard. Investors are weighing whether this regulatory milestone combined with strong cash flow generation can lead to a valuation increase or if ongoing headwinds will limit growth.
